CD163 and lobular neoplasia: To our knowledge no study has addressed the clinical threshold for urine sCD163/creatinuria ratio to discriminate LN-A in real world cases, therefore 320 ng/mmol was selected from the ROC curve as this value presented a specificity of 100 % (95 % CI: 92.9–100 % for both), a sensitivity of 92.5 % (95 % CI: 83.7–96.8 %) and 85.0 % (95 % CI: 75.6–91.2 %), a PPV of 90.9 % (95 % CI: 80.4–96.1 %) and 84.7 % (95 % CI: 73.5–91.8 %), and a NPV of 100 % for both (95 % CI: 94.2–100 % and 94.9–100 %) to differentiate LN-A from LN-IR and from non-LN groups, respectively.